Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
2 hedge funds and large institutions have $520K invested in Clovis Oncology, Inc. in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 13 closing their positions.
1% less capital invested
Capital invested by funds: $525K → $520K (-$4.37K)
87% less funds holding
Funds holding: 15 → 2 (-13)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RMC
Resources Management Corp
West Hartford,
Connecticut
|
+$510K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$479K |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$13K |
| 3 |
CAS
Coppell Advisory Solutions
Coppell,
Texas
|
-$12.7K |
| 4 |
CASC
Coppell Advisory Solutions Corp
Coppell,
Texas
|
-$12.7K |
| 5 |
STB
S&T Bank
Indiana,
Pennsylvania
|
-$3K |
CLVS Hedge Fund Activity: Q1 2023 in Review
2 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2023, worth a combined $520K — down 0.83% from $525K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CLVS and 0 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Resources Management Corp, adding an estimated $510K. The largest seller was IFP Advisors, exiting entirely with an estimated $479K sold.
- 2 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2023, down from 15 in Q4 2022.
- Funds reported $520K of Clovis Oncology, Inc. stock for Q1 2023, down 0.83% quarter-over-quarter.
- 0 funds opened new Clovis Oncology, Inc. positions in Q1 2023 and 13 closed out, a net change of -13 holders.
- The largest Clovis Oncology, Inc. buyer in Q1 2023 was Resources Management Corp, an estimated $510K added.
- The largest Clovis Oncology, Inc. seller in Q1 2023 was IFP Advisors, an estimated $479K sold.
Based on aggregated 13F filings for Q1 2023.